Is IDYA or RLMD more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Relmada Therapeutics N/A -71.22% -64.46%

Does the media prefer IDYA or RLMD?

In the previous week, Relmada Therapeutics had 16 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 17 mentions for Relmada Therapeutics and 1 mentions for IDEAYA Biosciences. Relmada Therapeutics' average media sentiment score of 1.05 beat IDEAYA Biosciences' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, RLMD or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is RLMD or IRON more profitable?

Disc Medicine's return on equity of -36.94% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Disc Medicine N/A -36.94% -33.88%

Does the media refer more to RLMD or IRON?

In the previous week, Relmada Therapeutics had 6 more articles in the media than Disc Medicine. MarketBeat recorded 17 mentions for Relmada Therapeutics and 11 mentions for Disc Medicine. Relmada Therapeutics' average media sentiment score of 1.05 beat Disc Medicine's score of 0.09 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ELVN or RLMD?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is ELVN or RLMD more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Relmada Therapeutics N/A -71.22% -64.46%

Does the media favor ELVN or RLMD?

In the previous week, Relmada Therapeutics had 13 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Relmada Therapeutics and 4 mentions for Enliven Therapeutics. Relmada Therapeutics' average media sentiment score of 1.05 beat Enliven Therapeutics' score of 0.12 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RLMD or TARS?

In the previous week, Relmada Therapeutics had 5 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 17 mentions for Relmada Therapeutics and 12 mentions for Tarsus Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.05 beat Tarsus Pharmaceuticals' score of -0.09 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, KLRA or RLMD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is KLRA or RLMD more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Relmada Therapeutics N/A -71.22% -64.46%

Relmada Therapeutics (RLMD) Competitors

$6.90 +0.13 (+1.92%)

As of 11:36 AM Eastern

Compare

RLMD vs. IDYA, IRON, ELVN, TARS, and KLRA

Should you buy Relmada Therapeutics stock or one of its competitors? MarketBeat compares Relmada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relmada Therapeutics include IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Enliven Therapeutics (ELVN), Tarsus Pharmaceuticals (TARS), and Kailera Therapeutics (KLRA). These companies are all part of the "pharmaceutical products" industry.

How does Relmada Therapeutics compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

IDEAYA Biosciences presently has a consensus target price of $50.69, indicating a potential upside of 37.52%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 73.91%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IDEAYA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

IDEAYA Biosciences' return on equity of -14.24% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Relmada Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.81	-$113.70M	-$1.60	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

In the previous week, Relmada Therapeutics had 16 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 17 mentions for Relmada Therapeutics and 1 mentions for IDEAYA Biosciences. Relmada Therapeutics' average media sentiment score of 1.05 beat IDEAYA Biosciences' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats IDEAYA Biosciences on 9 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to Disc Medicine?

Relmada Therapeutics (NASDAQ:RLMD) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Relmada Therapeutics had 6 more articles in the media than Disc Medicine. MarketBeat recorded 17 mentions for Relmada Therapeutics and 11 mentions for Disc Medicine. Relmada Therapeutics' average media sentiment score of 1.05 beat Disc Medicine's score of 0.09 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Disc Medicine is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Relmada Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Relmada Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 73.91%. Disc Medicine has a consensus target price of $105.80, suggesting a potential upside of 49.03%. Given Relmada Therapeutics' higher possible upside, equities research analysts plainly believe Relmada Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Disc Medicine's return on equity of -36.94% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Relmada Therapeutics beats Disc Medicine on 8 of the 13 factors compared between the two stocks.

How does Relmada Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

In the previous week, Relmada Therapeutics had 13 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Relmada Therapeutics and 4 mentions for Enliven Therapeutics. Relmada Therapeutics' average media sentiment score of 1.05 beat Enliven Therapeutics' score of 0.12 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Enliven Therapeutics presently has a consensus price target of $63.40, suggesting a potential upside of 27.16%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 73.91%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Enliven Therapeutics' return on equity of -21.04% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Relmada Therapeutics beats Enliven Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Relmada Therapeutics compare to Tarsus Pharmaceuticals?

Relmada Therapeutics (NASDAQ:RLMD) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Relmada Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 73.91%. Tarsus Pharmaceuticals has a consensus target price of $90.67, indicating a potential upside of 32.65%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Relmada Therapeutics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Tarsus Pharmaceuticals	$535.08M	5.50	-$66.42M	-$1.14	N/A

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Relmada Therapeutics had 5 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 17 mentions for Relmada Therapeutics and 12 mentions for Tarsus Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.05 beat Tarsus Pharmaceuticals' score of -0.09 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Summary

Relmada Therapeutics beats Tarsus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Relmada Therapeutics (NASDAQ:RLMD) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 90.00%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 73.91%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kailera Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

45.2% of Relmada Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

In the previous week, Relmada Therapeutics had 17 more articles in the media than Kailera Therapeutics. MarketBeat recorded 17 mentions for Relmada Therapeutics and 0 mentions for Kailera Therapeutics. Relmada Therapeutics' average media sentiment score of 1.05 beat Kailera Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kailera Therapeutics	Neutral
Relmada Therapeutics	Positive

Kailera Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Kailera Therapeutics and Relmada Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$717.97M	$3.00B	$6.55B	$12.21B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-6.28	18.65	24.98	24.15
Price / Sales	N/A	479.19	550.37	122.48
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	5.85	4.18	10.79	6.51
Net Income	-$57.38M	$64.45M	$3.56B	$337.14M
7 Day Performance	4.55%	2.56%	1.94%	0.21%
1 Month Performance	-1.99%	2.05%	1.39%	1.17%
1 Year Performance	1,065.74%	25.44%	31.08%	28.90%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.2991 of 5 stars	$6.90 +1.9%	$12.00 +73.9%	+1,009.8%	$717.97M	N/A	N/A	10	Positive News Analyst Revision
IDYA IDEAYA Biosciences	2.2466 of 5 stars	$30.28 +0.2%	$50.69 +67.4%	+63.0%	$2.66B	$218.71M	N/A	80
IRON Disc Medicine	2.1629 of 5 stars	$69.42 -1.0%	$105.80 +52.4%	+36.3%	$2.65B	N/A	N/A	30	Insider Trade
ELVN Enliven Therapeutics	2.6772 of 5 stars	$43.44 +2.5%	$63.40 +46.0%	+139.5%	$2.64B	N/A	N/A	50	Insider Trade
TARS Tarsus Pharmaceuticals	2.8802 of 5 stars	$60.95 -1.5%	$90.67 +48.8%	+63.0%	$2.62B	$451.36M	N/A	50	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. IDYA, IRON, ELVN, TARS, and KLRA

How does Relmada Therapeutics compare to IDEAYA Biosciences?

Summary

How does Relmada Therapeutics compare to Disc Medicine?

Summary

How does Relmada Therapeutics compare to Enliven Therapeutics?

Summary

How does Relmada Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Relmada Therapeutics compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. IDYA, IRON, ELVN, TARS, and KLRA

How does Relmada Therapeutics compare to IDEAYA Biosciences?

Do analysts recommend IDYA or RLMD?

Do institutionals & insiders believe in IDYA or RLMD?

Which has more volatility and risk, IDYA or RLMD?

Is IDYA or RLMD more profitable?

Which has better earnings and valuation, IDYA or RLMD?

Does the media prefer IDYA or RLMD?

Summary

How does Relmada Therapeutics compare to Disc Medicine?

Does the media refer more to RLMD or IRON?

Do insiders and institutionals hold more shares of RLMD or IRON?

Which has higher earnings & valuation, RLMD or IRON?

Which has more risk and volatility, RLMD or IRON?

Do analysts recommend RLMD or IRON?

Is RLMD or IRON more profitable?

Summary

How does Relmada Therapeutics compare to Enliven Therapeutics?

Does the media favor ELVN or RLMD?

Which has more volatility and risk, ELVN or RLMD?

Do insiders and institutionals have more ownership in ELVN or RLMD?

Do analysts rate ELVN or RLMD?

Which has better valuation and earnings, ELVN or RLMD?

Is ELVN or RLMD more profitable?

Summary

How does Relmada Therapeutics compare to Tarsus Pharmaceuticals?

Which has more risk & volatility, RLMD or TARS?

Do analysts recommend RLMD or TARS?

Which has better valuation & earnings, RLMD or TARS?

Do insiders & institutionals believe in RLMD or TARS?

Does the media favor RLMD or TARS?

Is RLMD or TARS more profitable?

Summary

How does Relmada Therapeutics compare to Kailera Therapeutics?

Do analysts rate KLRA or RLMD?

Do institutionals & insiders hold more shares of KLRA or RLMD?

Which has better earnings & valuation, KLRA or RLMD?

Does the media prefer KLRA or RLMD?

Is KLRA or RLMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools